Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim(Seoul National University), Seung Woon Paik(National Cancer Center), Joon Hyeok Lee(Samsung Medical Center), Geum‐Youn Gwak(Samsung Medical Center), Kwang Cheol Koh(Samsung Medical Center), Yong‐Han Paik(Samsung (South Korea)), Dong Hyun Sinn(Samsung (South Korea)), Moon Seok Choi(Samsung Medical Center), Wonseok Kang(Samsung Medical Center)
Cited by 88
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Toll–Like Receptor 4 Mediates Inflammatory Signaling by Bacterial Lipopolysaccharide in Human Hepatic Stellate Cells
|Hepatology|2003|643
Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma
|Experimental & Molecular Medicine|2015|423
Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 3
|Journal of Viral Hepatitis|2015|159